These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 17401460)
1. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460 [TBL] [Abstract][Full Text] [Related]
2. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188 [TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688 [TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Dong J; Xiao L; Sheng L; Xu J; Sun ZQ Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454 [TBL] [Abstract][Full Text] [Related]
6. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841 [TBL] [Abstract][Full Text] [Related]
7. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440 [TBL] [Abstract][Full Text] [Related]
8. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239 [TBL] [Abstract][Full Text] [Related]
9. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092 [TBL] [Abstract][Full Text] [Related]
10. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455 [TBL] [Abstract][Full Text] [Related]